Last updated: February 25, 2026
What is NDC 31722-0007?
NDC 31722-0007 is Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for spinal muscular atrophy (SMA) in pediatric patients. It is an intravenous single-dose treatment approved by the FDA in 2019. The therapy targets infants and young children with SMA and is considered a high-cost specialty biologic.
Market Size and Demand
Prevalence and Patient Population
- SMA is a rare genetic disorder affecting approximately 1 in 10,000 live births.
- Estimated number of eligible infants in the U.S.: 350-400 annually.
- Global market potential includes approximately 4,000-5,000 patients annually, based on SMA incidence rates and approval scope.
Current Treatment Landscape
- Standard treatments include nusinersen (Spinraza, Biogen) and risdiplam (Evrysdi, Roche).
- Zolgensma holds a unique position as a one-time gene therapy with a favorable administration profile compared to chronic dosing.
Key Market Dynamics
- Patent exclusivity for Zolgensma extends into the late 2020s.
- Competition from other SMA treatments influences market share distribution.
- Increasing diagnosis rates due to newborn screening programs expand the eligible patient pool.
Historical Sales Data
- In 2021, Novartis reported approximately $535 million in global sales of Zolgensma.
- Sales increased by 85% from the previous year, driven by approval in additional territories and expanded indications.
- U.S. sales comprised around 80% of global revenue, reflecting high adoption rates.
Pricing Analysis
Current Pricing Structure
- List price per dose in the U.S.: approximately $2.125 million.
- Cost includes a single infusion administered in a hospital setting.
- Price varies by country due to regulatory and reimbursement policies, generally ranging from $1.8 million to $2.2 million.
Cost Comparison with Competitors
| Treatment |
Treatment Type |
Dosing Schedule |
List Price |
| Zolgensma |
Gene therapy |
Single intravenous dose |
~$2.125 million in the U.S. |
| Spinraza (Nusinersen) |
Antisense oligonucleotide |
Repeated injections (monthly/quarterly) |
~$750,000 initial, then ~$125,000 every 4 months |
| Evrysdi (Risdiplam) |
Small molecule |
Daily oral administration |
Approx. $340,000 annually |
Reimbursement Landscape
- Coverage negotiated through payers with varying degrees of prior authorization requirements.
- Value-based agreements and installment payment options exist, especially in the U.S.
- Price adjustments and discounts are common in international markets.
Price Projection Factors
Short-Term Outlook (Next 2 Years)
- Continued healthcare provider familiarity and increasing diagnosis rates should sustain high demand.
- Reimbursement negotiations may lead to slight price reductions in certain markets.
- Market penetration stabilizes as most eligible patients receive treatment.
Long-Term Outlook (Next 5-10 Years)
- Introduction of biosimilars is unlikely due to the nature of gene therapies and current IP protections.
- Potential for price reductions as the therapy becomes more established and generic manufacturing becomes feasible.
- Expansion of indications (e.g., later-onset SMA) could increase patient population and revenue.
Estimated Price Trends
| Year |
Price Range in the U.S. |
Key Drivers |
| 2023 |
$2.1 - $2.2 million |
Stable demand, reimbursement negotiations |
| 2025 |
$2.0 - $2.2 million |
Market saturation, cost management strategies |
| 2030 |
$1.8 - $2.0 million |
Increased competition, manufacturing efficiencies |
Licensing and Patent Outlook
- Key patents protect Zolgensma until at least 2027-2028.
- Patent expirations could affect pricing and market penetration.
Implications for Stakeholders
- Pharma companies: Limited near-term risk of biosimilar competition; focus on expanding indications.
- Payers: Price negotiations and coverage policies influence market accessibility.
- Investors: High valuation based on patent exclusivity and growth potential; expect stabilization as competition approaches.
Key Takeaways
- NDC 31722-0007 (Zolgensma) is a high-cost gene therapy with significant market potential due to its unique one-time dosing.
- U.S. prices are around $2.125 million, with international variations.
- Sales are projected to experience modest declines over the next decade due to patent protections and market saturation.
- Price reductions are unlikely soon but could occur once patent protections expire or biosimilar options emerge.
- The company's strategic focus is on expanding indications and optimizing reimbursement.
FAQs
Q1: Will the price of Zolgensma decrease after patent expiration?
A1: Likely. Patent expirations could enable biosimilar development, reducing prices and increasing accessibility.
Q2: How does Zolgensma compare to other SMA treatments in cost?
A2: It has a higher upfront cost, approximately $2.125 million, versus ongoing treatment costs for Spinraza and Evrysdi, which are lower annually but involve recurrent dosing.
Q3: Are there plans for price adjustments in the near term?
A3: Price adjustments are expected to be minimal in the short term, driven mainly by negotiations and market access strategies.
Q4: What drives future demand for Zolgensma?
A4: Improved diagnosis through newborn screening, expanded approval for older patients, and increasing SMA awareness.
Q5: How do reimbursement policies impact pricing?
A5: They influence net revenue; payers often negotiate discounts and installment plans, affecting effective pricing strategies.
References
[1] Novartis. (2022). Zolgensma (onasemnogene abeparvovec-xioi) product information.
[2] IQVIA. (2022). Global gene therapy market report.
[3] U.S. Food and Drug Administration. (2019). Zolgensma approval announcement.
[4] EvaluatePharma. (2022). Oncology and rare disease drug price trends.
[5] Centers for Disease Control and Prevention. (2021). SMA prevalence and diagnosis statistics.
